News & Events


Friday September 10, 2021

Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021

- Long-term Data from KINECT 4 Study Found that Long-Term Tardive Dyskinesia (TD) Symptom Reductions were Achieved with Once-Daily INGREZZA - New Pooled Analysis of Two Phase 3 Studies Found Treatment with ONGENTYS as an Add-On to Levodopa/Carbidopa Decreased the Frequency of Nighttime Awakenings

Thursday September 02, 2021

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO , Sept. 2, 2021 /PRNewswire/ --  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following virtual investor conferences:     Kevin Gorman , Chief Executive Officer, will present at the Morgan Stanley 19 th Annual

Thursday August 05, 2021

Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease

- Top-Line Readout of Clinical Study Results Anticipated by the End of 2021 - Initiating Expanded Enrollment to New Participants in Open-Label Extension Study KINECT-HD2 SAN DIEGO , Aug. 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with the Huntington Study

Tuesday August 03, 2021

Neurocrine Biosciences Reports Second Quarter 2021 Financial Results

INGREZZA® (valbenazine) Second Quarter 2021 Net Product Sales of $265 Million with Approximately 48,900 Total Prescriptions Phase 3 Registrational Program of Valbenazine for the Treatment of Chorea Associated with Huntington Disease Fully Enrolled with Top-Line Data Expected by Year-End SAN DIEGO ,

Thursday July 22, 2021

Neurocrine Biosciences/The Harris Poll Survey: 8 in 10 Americans Will Always Prefer In-Person Doctor Appointments to Telehealth

Patients Overall Satisfied with Telehealth Care Received During the Pandemic but also Worry Things Will Be Missed on Telehealth SAN DIEGO, July 22, 2021 – A new Neurocrine Biosciences, Inc. (Nasdaq: NBIX) survey conducted by The Harris Poll found that 80% of Americans will always prefer in-person